1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

Identification

Generic Name
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
DrugBank Accession Number
DB01562
Background

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP) is a synthetic analogue of meperidine. It is sold as a "synthetic heroin."

Type
Small Molecule
Groups
Experimental, Illicit
Structure
Weight
Average: 323.4287
Monoisotopic: 323.188529049
Chemical Formula
C21H25NO2
Synonyms
  • 1-(2-Phenethyl)-4-phenyl-4-acetoxypiperidine
  • 1-Phenethyl-4-phenyl-4-piperidinol acetate (ester)
  • PEPAP
External IDs
  • DEA No. 9663
  • IDS-NP-026
  • IDS-NP-026(SECT.3)
  • MCV 4527
  • NIH 10460

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe metabolism of Acebutolol can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Benzyloxycarbonyls / Phenethylamines / Aralkylamines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Benzyloxycarbonyl / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
T6LN72I828
CAS number
64-52-8
InChI Key
BVURVTVDNWSNFN-UHFFFAOYSA-N
InChI
InChI=1S/C21H25NO2/c1-18(23)24-21(20-10-6-3-7-11-20)13-16-22(17-14-21)15-12-19-8-4-2-5-9-19/h2-11H,12-17H2,1H3
IUPAC Name
4-phenyl-1-(2-phenylethyl)piperidin-4-yl acetate
SMILES
CC(=O)OC1(CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1

References

General References
  1. Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM: Designer drugs that are potent inhibitors of CYP2D6. J Clin Psychopharmacol. 2002 Jun;22(3):330-2. doi: 10.1097/00004714-200206000-00015. [Article]
PubChem Compound
60977
PubChem Substance
46505389
ChemSpider
54939
ChEMBL
CHEMBL2361014

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00592 mg/mLALOGPS
logP4.18ALOGPS
logP3.61Chemaxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.24Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area29.54 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity96.73 m3·mol-1Chemaxon
Polarizability37.55 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.988
Blood Brain Barrier+0.9787
Caco-2 permeable+0.6548
P-glycoprotein substrateSubstrate0.6775
P-glycoprotein inhibitor IInhibitor0.8302
P-glycoprotein inhibitor IIInhibitor0.5604
Renal organic cation transporterInhibitor0.7384
CYP450 2C9 substrateNon-substrate0.8006
CYP450 2D6 substrateNon-substrate0.7419
CYP450 3A4 substrateSubstrate0.6116
CYP450 1A2 substrateNon-inhibitor0.8011
CYP450 2C9 inhibitorNon-inhibitor0.803
CYP450 2D6 inhibitorInhibitor0.7905
CYP450 2C19 inhibitorNon-inhibitor0.8544
CYP450 3A4 inhibitorInhibitor0.5866
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6531
Ames testNon AMES toxic0.8532
CarcinogenicityNon-carcinogens0.8846
BiodegradationNot ready biodegradable0.9685
Rat acute toxicity2.7903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.6423
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0049000000-1a7ea63a7c45b16fc629
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-448ab03443271bae92e8
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a59-7192000000-3e3d75454b0a18265ff5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0293000000-36b536e24899c7a38e28
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-5950000000-6ee35ab6b2d1e833f1c5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08ml-3912000000-938104204193feddcb1d
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-184.8253039
predicted
DarkChem Lite v0.1.0
[M-H]-170.02551
predicted
DeepCCS 1.0 (2019)
[M+H]+185.4262039
predicted
DarkChem Lite v0.1.0
[M+H]+172.38351
predicted
DeepCCS 1.0 (2019)
[M+Na]+185.4521039
predicted
DarkChem Lite v0.1.0
[M+Na]+178.7459
predicted
DeepCCS 1.0 (2019)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
This enzyme action is supported by an in vitro study. Clinical correlation is unknown.
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM: Designer drugs that are potent inhibitors of CYP2D6. J Clin Psychopharmacol. 2002 Jun;22(3):330-2. doi: 10.1097/00004714-200206000-00015. [Article]

Drug created at July 31, 2007 13:10 / Updated at June 12, 2020 16:51